|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3.
|
Tseng CW, Yang JC, Chen CN, et al:
Identification of 14-3-3beta in human gastric cancer cells and its
potency as a diagnostic and prognostic biomarker. Proteomics.
11:2423–2439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kobayashi Y, Niwa Y, Tajika M, et al:
Serum tumor antigen REG4 as a useful diagnostic biomarker in
gastric cancer. Hepatogastroenterology. 57:1631–1634.
2010.PubMed/NCBI
|
|
5.
|
Yang S and Chung HC: Novel biomarker
candidates for gastric cancer. Oncol Rep. 19:675–680.
2008.PubMed/NCBI
|
|
6.
|
Chan DC, Chen CJ, Chu HC, et al:
Evaluation of serum amyloid A as a biomarker for gastric cancer.
Ann Surg Oncol. 14:84–93. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Poon TC: Opportunities and limitations of
SELDI-TOF-MS in biomedical research: practical advices. Expert Rev
Proteomics. 4:51–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Cho WC: Research progress in SELDI-TOF MS
and its clinical applications. Sheng Wu Gong Cheng Xue Bao.
22:871–876. 2006.(In Chinese).
|
|
9.
|
Clarke CH, Buckley JA and Fung ET:
SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med.
43:1314–1320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Liu C: The application of SELDI-TOF-MS in
clinical diagnosis of cancers. J Biomed Biotechnol.
2011:2458212011.PubMed/NCBI
|
|
11.
|
Caffrey RE: A review of experimental
design best practices for proteomics based biomarker discovery:
focus on SELDI-TOF. Methods Mol Biol. 641:167–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kristina G, Radomir P, Eva B, et al: When
one chip is not enough: augmenting the validity of SELDI-TOF
proteomic profiles of clinical specimens. Lab Chip. 9:1014–1017.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Liu W, Gao X, Cai Q, et al: Identification
of novel serum biomarkers for gastric cancer by magnetic bead.
Front Biosci (Elite Ed). 2:961–971. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Huang Q, Chen W, Wang L, Lin W, Lin J and
Lin X: Identification of transgelin as a potential novel biomarker
for gastric adenocarcinoma based on proteomics technology. J Cancer
Res Clin Oncol. 134:1219–1227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Umemura H, Togawa A, Sogawa K, et al:
Identification of a high molecular weight kininogen fragment as a
marker for early gastric cancer by serum proteome analysis. J
Gastroenterol. 46:577–585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wang J, Yu JC, Kang WM and Ma ZQ:
Treatment strategy for early gastric cancer. Surg Oncol. Jan
21–2011.(Epub ahead of print).
|
|
17.
|
Saka M, Morita S, Fukagawa T and Katai H:
Present and future status of gastric cancer surgery. Jpn J Clin
Oncol. 41:307–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Cho WC: Proteomics technologies and
challenges. Genomics Proteomics Bioinformatics. 5:77–85. 2007.
View Article : Google Scholar
|
|
19.
|
Cho WC: Contribution of oncoproteomics to
cancer biomarker discovery. Mol Cancer. 6:252007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lei L, Wang XJ, Zheng ZG, et al:
Identification of serum protein markers for breast cancer relapse
with SELDI-TOF MS. Anat Rec (Hoboken). 294:941–944. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Felix K, Fakelman F, Hartmann D, et al:
Identification of serum proteins involved in pancreatic cancer
cachexia. Life Sci. 88:218–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Liu L, Liu J, Wang Y, et al: A combined
biomarker pattern improves the discrimination of lung cancer.
Biomarkers. 16:20–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Hogdall E, Fung ET, Christensen IJ, et al:
Proteomic biomarkers for overall and progression-free survival in
ovarian cancer patients. Proteomics Clin Appl. 4:940–952. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Gemoll T, Roblick UJ, Auer G, Jornvall H
and Habermann JK: SELDI-TOF serum proteomics and colorectal cancer:
a current overview. Arch Physiol Biochem. 116:188–196. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Konstantopoulos K and Thomas SN: Cancer
cells in transit: the vascular interactions of tumor cells. Annu
Rev Biomed Eng. 11:177–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Costantini V and Zacharski LR: The role of
fibrin in tumor metastasis. Cancer Metastasis Rev. 11:283–290.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Vanhollebeke B and Pays E: The function of
apolipoproteins L. Cell Mol Life Sci. 63:1937–1944. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Ashe PC and Berry MD: Apoptotic signaling
cascades. Prog Neuropsychopharmacol Biol Psychiatry. 27:199–214.
2003. View Article : Google Scholar
|
|
29.
|
Engwegen JY, Helgason HH, Cats A, et al:
Identification of serum proteins discriminating colorectal cancer
patients and healthy controls using surface-enhanced laser
desorption ionisation-time of flight mass spectrometry. World J
Gastroenterol. 12:1536–1544. 2006.
|
|
30.
|
Fan Y, Wang J, Yang Y, et al: Detection
and identification of potential biomarkers of breast cancer. J
Cancer Res Clin Oncol. 136:1243–1254. 2010. View Article : Google Scholar : PubMed/NCBI
|
